KN
Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ
79.36
+0.33 (+0.41%)
Closed
Aug 24, 2026
Day's Range
78.0179.98
52 wk Range
32.8982.94
Financial Statements - KNSA - Kiniksa Pharmaceuticals International, plc
Revenue
677.56M▲ 60.1%
Net Income
59.00M▲ 236.6%Net Margin 8.7%
EBITDA
78.77M▲ 279.4%
Free Cash Flow
136.41M▲ 436.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 677.56M | 423.23M | 270.25M | 220.18M | 38.54M | 0 |
| Cost of Goods | 307.21M | 60.91M | 33.40M | 22.89M | 9.10M | 0 |
| Gross Profit | 370.34M | 362.32M | 236.85M | 197.28M | 29.44M | 0 |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 77.22M | -45.61M | -25.19M | 9.77M | -156.63M | -157.36M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 11.64M | 9.46M | 8.54M | 1.25M | 97K | - |
| Pre Tax Income | 88.86M | -36.15M | -16.65M | 11.02M | -156.53M | -156.22M |
| Income Tax | 29.86M | 7.04M | -30.73M | -172.33M | 1.38M | 5.15M |
| Net Income | 59M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M |
| EPS Basic | 0.8 | -0.6 | 0.2 | 2.64 | -2.3 | -2.61 |
| EPS Diluted | 0.75 | -0.6 | 0.2 | 2.6 | -2.3 | -2.61 |
| Basic Shares Outstanding | 74.20M | 71.42M | 70.05M | 69.38M | 68.57M | 61.84M |
| Diluted Shares Outstanding | 74.20M | 71.42M | 70.05M | 69.38M | 68.57M | 61.84M |
| Ebit | 77.22M | -45.61M | -25.19M | 9.77M | -156.63M | -157.36M |
| Ebitda | 78.77M | -43.92M | -22.85M | 12.17M | -154.28M | -154.95M |
| Net Income Continuous Operations | 59M | -43.19M | 14.08M | 183.36M | -157.92M | -161.38M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
